CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nanobac Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nanobac Pharmaceuticals, Inc.
5025 W Lemon St
Phone: (813) 377-4434p:813 377-4434 TAMPA, FL  33609-1101  United States Ticker: NNBPNNBP

This company ceased filing statements with the SEC on 5/20/2011.

Business Summary
Nanobac Pharmaceuticals, Incorporated (Nanobac) is a research-based, bio-lifescience company. The Company is primarily engaged in the discovery and development of products and services to improve people’s health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as nanobacteria. Its research is directed toward establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease. Nanobac’s drug discovery and development is focused on new and existing compounds that inhibit, destroy or neutralize CNPs. Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products (blood and tissue tests) include assays, antibodies and reagents for recognizing CNPs.
(Source: 10KSB)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/200712/31/2007YesYes---

Industries
SIC Code Description
8071 Medical laboratories
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer, Chief Financial Officer John D.Stanton 63 7/23/2004 11/1/2000
Director Alexander H.Edwards 46 7/1/2004 3/1/2003
Director Benedict S.Maniscalco 71 3/29/2006 3/29/2006
Director StephenRechtschaffen 63 2/2/2004 2/2/2004

Business Names
Business Name
American Enterprise.Com
American Enterprise.com Corp.
Nanobac OY
11 additional Business Names available in full report.

General Information
Number of Employees: 1 (As of 12/31/2007)
Outstanding Shares: 249,506,760 (As of 12/31/2007)
Shareholders: 250
Stock Exchange: OTC
Federal Tax Id: 593248917
Email Address: info@nanobaclabs.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023